Non Small Cell Lung Cancer Metastatic Clinical Trial
Official title:
Use of Response-Adapted Hypofractionated Radiation Therapy to Potentiate the Systemic Immune Response to Checkpoint Inhibitors in Non-Small Cell Lung Cancer
This study includes the additional use of radiation therapy in combination immunotherapy in order to determine whether the radiation may improve the response of non-small cell lung cancer to immunotherapy and to monitor any side effects.
Preclinical data suggest that radiation therapy may be uniquely suited to combine with immune checkpoint inhibitors, since radiation can disrupt a tumor's physical barriers to T-cell infiltration and augment antigen presentation, thus serving as an "in situ personalized vaccine" to activate the immune system and potentially enhance the systemic response. The rationale for this study is to determine the safety and efficacy of combined immune checkpoint inhibitors and radiation therapy in metastatic non-small cell lung cancer patients. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03168464 -
Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05117242 -
Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer
|
Phase 2 | |
| Completed |
NCT04470440 -
Thyroid Dysfunction and Nivolumab Reponse in NSCLC
|
||
| Completed |
NCT03304093 -
Immunotherapy by Nivolumab for HIV+ Patients
|
Phase 2 | |
| Terminated |
NCT04069936 -
Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC
|
Phase 2 | |
| Active, not recruiting |
NCT03307785 -
Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042
|
Phase 1 | |
| Recruiting |
NCT06100796 -
Effect of DM on Outcomes and Response Rate in Patients With Advanced NSCLC on ICI
|
||
| Recruiting |
NCT03533127 -
A Study of LY01008 and Bevacizumab Combined With Paclitaxel and Carboplatin for Treatment of Naïve Subjects With Metastatic or Recurrent Nonsquamous Non-small Cell Lung Cancer
|
Phase 3 | |
| Completed |
NCT04187768 -
Immunological Profile Changes In Patients With Advanced Non-Small Cell Lung Cancer
|
||
| Active, not recruiting |
NCT04951583 -
Fecal Microbial Transplantation Non-Small Cell Lung Cancer and Melanoma
|
Phase 2 | |
| Active, not recruiting |
NCT03133546 -
Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M (BOOSTER)
|
Phase 2 | |
| Completed |
NCT03845270 -
Her2-positive Lung Cancer Treated With Dedicated Drug
|
Phase 2 | |
| Recruiting |
NCT05864794 -
Value of Screening MRI Brain in Stage IV Non-small Cell Lung Cancer
|
N/A | |
| Recruiting |
NCT05274451 -
A Study to Investigate LYL797 in Adults With Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT03774732 -
PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer
|
Phase 3 | |
| Recruiting |
NCT04621188 -
Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)
|
Phase 2 | |
| Recruiting |
NCT06378892 -
A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib
|
Phase 2 | |
| Active, not recruiting |
NCT03235765 -
Cancer Panel From Blood of Lung Cancer Patients
|
||
| Not yet recruiting |
NCT03732482 -
Temozolomide Combine With Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost for Non Small Cell Lung Cancer Brain Metastases
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT02978404 -
Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases
|
Phase 2 |